Retrovax KYC Verification

KYC Verification has expired

As we clearly state on our website, we keep the information obtained during the KYC process for 1 year.
After 1 year, we permanently delete all information.
For the reason we explained above, all information about this project has been deleted since 1 year has passed.

Project Information

Project Name: Retrovax

Ticker/Symbol: RTX

Contract: 0x35c13d740cfDc30285C19aaDd158e3095E29707a

Network: BSC (Binance Smart Chain)

Website: https://www.retrovax.co/

Telegram: https://t.me/joinchat/M9YOAmBLJa9iMzZk

Twitter:https://twitter.com/retrovax_co

Presale address: DxSale

For presale details, you should join the Retrovax Telegram group.

Join IDopresales Telegram channel

What is KYC Service?

During the KYC process, the identities of the team members and their connection to the project were determined.

Team members provided important documents for these determinations.

What does it mean?

KYC mainly aims to protect investors against scam-rug pull.

If team members scam people:

We will file a criminal complaint against them in the country they are in with the documents they provide to us.
We will reveal their identities.

To investors: If you think a project that has passed our KYC process is a scam or rug pull, let us know. Please also explain why you think so. Our team will review your submissions and, if true, will reveal the identity of the project owners.

Disclaimer
The fact that a project passes KYC service does not mean that we approve and recommend that project. The KYC service includes the identification of the project owner. Therefore, this service will assist the decision-making process of investors. Please DYOR.

Retrovax Project

Retrovax is an ambitious project whose aim is to solve a problem that humanity has been carrying around for decades: the spread of HIV and related deaths.

Retrovax was born from an Italian team of students and visionaries, that wanted to create financial stability for the goal they would pursue: begin the study and development of a definitive HIV Vaccine. To do this, the company will collaborate with the universities of Milan and Turin, located in Italy.

For more info, please read White Paper